Celanese Corporation is a leading global specialty materials company that operates the Acetyl Chain and Engineered Materials businesses, and the question for the next twelve months is whether the company can sustain the second quarter 2026 earnings momentum as the highest in nearly three years into the second half of 2026 while executing the $50 million of annualized fixed-cost savings from the Ulsan, nylon 6,6, and Lanaken optimization initiatives. The Q2 2026 print was the cleanest test yet of that thesis, and the cleanest signal is that President and CEO Scott Richardson reported that the Q2 2026 adjusted earnings per share of $2.45 (inclusive of approximately $0.35 per share of non-cash transaction amortization) was the highest in nearly three years. The combination of the Q2 2026 adjusted EPS of $2.45, the operating EBITDA growth of more than 20 percent year over year, the Engineered Materials Q2 2026 adjusted EBIT of $234 million, the Engineered Materials Q2 2026 operating EBITDA of $335 million at margins of 16 percent and 23 percent respectively, the highest quarterly total variable margin contribution in the history of the Engineered Materials business, the Acetyl Chain leverage of the differentiated network across the Western Hemisphere, the completed closure of the EM compounding facility in Ulsan, South Korea with production transferred to more efficient assets, the completed ahead-of-schedule optimization of the nylon 6,6 manufacturing network, the on-track completion of the planned closure of the acetate tow facility in Lanaken, Belgium in the third quarter, the $50 million of annualized fixed-cost savings from the Grow Fortify strategy, the favorable pricing and mix outcomes in Engineered Materials, the momentum in medical and electronics strategic growth platforms, the supply disruptions that proved transitory to some extent especially in China, the disciplined pricing, reliable global supply, and differentiated capabilities of the product portfolio, and the strengthening cash generation to support deleveraging is the cleanest single read on what the Grow-Fortify-pivot is producing. The strategic tension is the supply disruptions against the second half 2026 normalization, and the forward question is whether the company can sustain the Q2 2026 adjusted EPS of $2.45 into the second half of 2026 and whether the $50 million of annualized fixed-cost savings can be realized as planned.